Multiple myeloma is a complex hematological malignancy that continues to represent a significant challenge for health systems, especially in countries like Colombia, where timely diagnosis and access to advanced diagnostic technologies still face structural and operational barriers. Its heterogeneous clinical presentation, silent progression in early stages and dependence on specialized tests mean that early detection continues to be one of the main challenges in daily medical practice.

In this context, the clinical laboratory is positioned as a fundamental axis in the approach to multiple myeloma. From the identification of initial biochemical alterations to diagnostic confirmation through immunological, cytogenetic and molecular studies, the laboratory not only accompanies the clinician, but also becomes a decisive actor in guiding the diagnosis, prognosis and therapeutic monitoring of the patient. However, the underuse of specialized tests, the fragmentation of the diagnostic process and the lack of articulation between the different levels of care continue to negatively impact diagnosis times.

Permanent academic updating is essential to face these challenges. Understanding advances in diagnostic criteria, new laboratory tools and the growing role of diagnostic technology allows us to close gaps between scientific evidence and real clinical practice. Likewise, the integration between healthcare medicine, clinical research and technological development emerges as a key strategy to improve outcomes in patients with multiple myeloma.

In this edition of In Vitro News, we present an interview with Dr. Jair Figueroa Emiliani, whose clinical and scientific career provides an expert vision on the current panorama of multiple myeloma in Colombia. Through their experience, we explore the main challenges in timely diagnosis, the strategic role of the clinical laboratory and the need to strengthen interdisciplinary collaboration as a way to optimize patient care and move towards more precise and timely medicine.